# Veeva Systems Inc: financial statements, quarterly

VEEV · NYSE · CIK 1393052 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/veev.md) · [Financials](/companies/veev/financials.md) · [Filings](/companies/veev/filings.md) · [Insiders](/companies/veev/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/veev/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [617](/filings/0001393052-24-000075.md) | [631 d](/filings/0001393052-26-000014.md) | [650](/filings/0001393052-25-000042.md) | [676](/filings/0001393052-25-000067.md) | [699](/filings/0001393052-25-000078.md) | [721 d](/filings/0001393052-26-000014.md) | [759](/filings/0001393052-26-000026.md) | [789](/filings/0001393052-26-000036.md) | [811](/filings/0001393052-25-000078.md) | [836 d](/filings/0001393052-26-000014.md) | [883](/filings/0001393052-26-000026.md) | [928](/filings/0001393052-26-000036.md) |
| Cost of revenue | $m | [168](/filings/0001393052-24-000075.md) | [174 d](/filings/0001393052-26-000014.md) | [174](/filings/0001393052-25-000042.md) | [170](/filings/0001393052-25-000067.md) | [174](/filings/0001393052-25-000078.md) | [181 d](/filings/0001393052-26-000014.md) | [174](/filings/0001393052-26-000026.md) | [195](/filings/0001393052-26-000036.md) | [199](/filings/0001393052-25-000078.md) | [213 d](/filings/0001393052-26-000014.md) | [221](/filings/0001393052-26-000026.md) | [232](/filings/0001393052-26-000036.md) |
| Gross profit | $m | [449](/filings/0001393052-24-000075.md) | [457 d](/filings/0001393052-26-000014.md) | [476](/filings/0001393052-25-000042.md) | [506](/filings/0001393052-25-000067.md) | [525](/filings/0001393052-25-000078.md) | [540 d](/filings/0001393052-26-000014.md) | [585](/filings/0001393052-26-000026.md) | [594](/filings/0001393052-26-000036.md) | [612](/filings/0001393052-25-000078.md) | [622 d](/filings/0001393052-26-000014.md) | [662](/filings/0001393052-26-000026.md) | [696](/filings/0001393052-26-000036.md) |
| Research and development | $m | [161](/filings/0001393052-24-000075.md) | [164 d](/filings/0001393052-26-000014.md) | [163](/filings/0001393052-25-000042.md) | [176](/filings/0001393052-25-000067.md) | [172](/filings/0001393052-25-000078.md) | [182 d](/filings/0001393052-26-000014.md) | [184](/filings/0001393052-26-000026.md) | [193](/filings/0001393052-26-000036.md) | [192](/filings/0001393052-25-000078.md) | [199 d](/filings/0001393052-26-000014.md) | [208](/filings/0001393052-26-000026.md) | [223](/filings/0001393052-26-000036.md) |
| Operating income | $m | [128](/filings/0001393052-24-000075.md) | [135 d](/filings/0001393052-26-000014.md) | [155](/filings/0001393052-25-000042.md) | [166](/filings/0001393052-25-000067.md) | [181](/filings/0001393052-25-000078.md) | [188 d](/filings/0001393052-26-000014.md) | [234](/filings/0001393052-26-000026.md) | [196](/filings/0001393052-26-000036.md) | [241](/filings/0001393052-25-000078.md) | [246 d](/filings/0001393052-26-000014.md) | [273](/filings/0001393052-26-000026.md) | [275](/filings/0001393052-26-000036.md) |
| Income tax | $m | [35.5](/filings/0001393052-24-000075.md) | [35.3 d](/filings/0001393052-26-000014.md) | [45.2](/filings/0001393052-25-000042.md) | [54.0](/filings/0001393052-25-000067.md) | [56.5](/filings/0001393052-25-000078.md) | [49.5 d](/filings/0001393052-26-000014.md) | [70.6](/filings/0001393052-26-000026.md) | [65.1](/filings/0001393052-26-000036.md) | [76.6](/filings/0001393052-25-000078.md) | [73.3 d](/filings/0001393052-26-000014.md) | [86.6](/filings/0001393052-26-000026.md) | [76.1](/filings/0001393052-26-000036.md) |
| Net income | $m | [135](/filings/0001393052-24-000075.md) | [147 d](/filings/0001393052-26-000014.md) | [162](/filings/0001393052-25-000042.md) | [171](/filings/0001393052-25-000067.md) | [186](/filings/0001393052-25-000078.md) | [196 d](/filings/0001393052-26-000014.md) | [228](/filings/0001393052-26-000026.md) | [200](/filings/0001393052-26-000036.md) | [236](/filings/0001393052-25-000078.md) | [244 d](/filings/0001393052-26-000014.md) | [261](/filings/0001393052-26-000026.md) | [273](/filings/0001393052-26-000036.md) |
| Diluted EPS | $ per share | [0.83](/filings/0001393052-24-000075.md) | not reported | [0.98](/filings/0001393052-25-000042.md) | [1.04](/filings/0001393052-25-000067.md) | [1.13](/filings/0001393052-25-000078.md) | not reported | [1.37](/filings/0001393052-26-000026.md) | [1.19](/filings/0001393052-26-000036.md) | [1.40](/filings/0001393052-25-000078.md) | not reported | [1.57](/filings/0001393052-26-000026.md) | [1.66](/filings/0001393052-26-000036.md) |
| Basic EPS | $ per share | [0.84](/filings/0001393052-24-000075.md) | not reported | [1.00](/filings/0001393052-25-000042.md) | [1.06](/filings/0001393052-25-000067.md) | [1.15](/filings/0001393052-25-000078.md) | not reported | [1.40](/filings/0001393052-26-000026.md) | [1.23](/filings/0001393052-26-000036.md) | [1.44](/filings/0001393052-25-000078.md) | not reported | [1.60](/filings/0001393052-26-000026.md) | [1.68](/filings/0001393052-26-000036.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [744](/filings/0001393052-24-000075.md) | [703](/filings/0001393052-26-000014.md) | [1,197](/filings/0001393052-25-000042.md) | [1,166](/filings/0001393052-25-000067.md) | [1,045](/filings/0001393052-25-000078.md) | [1,119](/filings/0001393052-26-000014.md) | [1,965](/filings/0001393052-26-000026.md) | [1,930](/filings/0001393052-26-000036.md) | [1,660](/filings/0001393052-25-000078.md) | [1,421](/filings/0001393052-26-000036.md) | [1,897](/filings/0001393052-26-000026.md) | [1,812](/filings/0001393052-26-000036.md) |
| Current assets | $m | [4,336](/filings/0001393052-23-000066.md) | [5,003](/filings/0001393052-25-000022.md) | [5,245](/filings/0001393052-24-000024.md) | [5,368](/filings/0001393052-24-000062.md) | [5,447](/filings/0001393052-24-000075.md) | [6,309](/filings/0001393052-26-000014.md) | [6,708](/filings/0001393052-25-000042.md) | [6,995](/filings/0001393052-25-000067.md) | [7,112](/filings/0001393052-25-000078.md) | [7,998](/filings/0001393052-26-000036.md) | [8,063](/filings/0001393052-26-000026.md) | [7,946](/filings/0001393052-26-000036.md) |
| Total assets | $m | [5,226](/filings/0001393052-23-000066.md) | [5,911](/filings/0001393052-25-000022.md) | [6,188](/filings/0001393052-24-000024.md) | [6,331](/filings/0001393052-24-000062.md) | [6,453](/filings/0001393052-24-000075.md) | [7,340](/filings/0001393052-26-000014.md) | [7,765](/filings/0001393052-25-000042.md) | [7,999](/filings/0001393052-25-000067.md) | [8,097](/filings/0001393052-25-000078.md) | [8,979](/filings/0001393052-26-000036.md) | [9,130](/filings/0001393052-26-000026.md) | [9,060](/filings/0001393052-26-000036.md) |
| Current liabilities | $m | [768](/filings/0001393052-23-000066.md) | [1,179](/filings/0001393052-25-000022.md) | [1,223](/filings/0001393052-24-000024.md) | [1,070](/filings/0001393052-24-000062.md) | [857](/filings/0001393052-24-000075.md) | [1,398](/filings/0001393052-26-000014.md) | [1,457](/filings/0001393052-25-000042.md) | [1,255](/filings/0001393052-25-000067.md) | [945](/filings/0001393052-25-000078.md) | [1,637](/filings/0001393052-26-000036.md) | [1,702](/filings/0001393052-26-000026.md) | [1,456](/filings/0001393052-26-000036.md) |
| Total liabilities | $m | [846](/filings/0001393052-23-000066.md) | [1,266](/filings/0001393052-25-000022.md) | [1,298](/filings/0001393052-24-000024.md) | [1,146](/filings/0001393052-24-000062.md) | [951](/filings/0001393052-24-000075.md) | [1,507](/filings/0001393052-26-000014.md) | [1,554](/filings/0001393052-25-000042.md) | [1,361](/filings/0001393052-25-000067.md) | [1,057](/filings/0001393052-25-000078.md) | [1,765](/filings/0001393052-26-000036.md) | [1,825](/filings/0001393052-26-000026.md) | [1,629](/filings/0001393052-26-000036.md) |
| Shareholders' equity | $m | [4,380](/filings/0001393052-24-000075.md) | [4,645](/filings/0001393052-26-000014.md) | [4,889](/filings/0001393052-25-000067.md) | [5,185](/filings/0001393052-25-000078.md) | [5,501](/filings/0001393052-25-000078.md) | [5,832](/filings/0001393052-26-000036.md) | [6,211](/filings/0001393052-26-000036.md) | [6,639](/filings/0001393052-26-000036.md) | [7,041](/filings/0001393052-25-000078.md) | [7,215](/filings/0001393052-26-000036.md) | [7,304](/filings/0001393052-26-000036.md) | [7,431](/filings/0001393052-26-000036.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [82.6](/filings/0001393052-23-000066.md) | [57.8 d](/filings/0001393052-26-000014.md) | [764](/filings/0001393052-25-000042.md) | [92.9 d](/filings/0001393052-25-000067.md) | [164 d](/filings/0001393052-25-000078.md) | [69.5 d](/filings/0001393052-26-000014.md) | [877](/filings/0001393052-26-000026.md) | [238 d](/filings/0001393052-26-000036.md) | [193 d](/filings/0001393052-25-000078.md) | [107 d](/filings/0001393052-26-000014.md) | [1,127](/filings/0001393052-26-000026.md) | [239 d](/filings/0001393052-26-000036.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001393052-26-000026.md) | [0.0 d](/filings/0001393052-26-000036.md) | not reported | not reported | [227](/filings/0001393052-26-000026.md) | [246 d](/filings/0001393052-26-000036.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [162](/filings/0001393052-23-000066.md) | [163](/filings/0001393052-24-000024.md) | [163](/filings/0001393052-24-000062.md) | [164](/filings/0001393052-24-000075.md) | [164](/filings/0001393052-25-000042.md) | [165](/filings/0001393052-25-000067.md) | [165](/filings/0001393052-25-000078.md) | [166](/filings/0001393052-26-000026.md) | [168](/filings/0001393052-26-000036.md) | [169](/filings/0001393052-25-000078.md) | [166](/filings/0001393052-26-000026.md) | [165](/filings/0001393052-26-000036.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 161,908,850 at 2026-08-25, from the cover of the [10-Q filed 2026-08-27](/filings/0001393052-26-000036.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.